GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (NAS:NYXH) » Definitions » Common Stock

Nyxoah (Nyxoah) Common Stock : $5.36 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nyxoah Common Stock?

Nyxoah's quarterly common stock increased from Sep. 2023 ($5.26 Mil) to Dec. 2023 ($5.37 Mil) but then declined from Dec. 2023 ($5.37 Mil) to Mar. 2024 ($5.36 Mil).

Nyxoah's annual common stock declined from Dec. 2021 ($5.00 Mil) to Dec. 2022 ($4.70 Mil) but then increased from Dec. 2022 ($4.70 Mil) to Dec. 2023 ($5.37 Mil).


Nyxoah Common Stock Historical Data

The historical data trend for Nyxoah's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Common Stock Chart

Nyxoah Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial 2.76 4.62 5.00 4.70 5.37

Nyxoah Quarterly Data
Dec17 Dec18 Jun19 Dec19 Mar20 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.20 5.34 5.26 5.37 5.36

Nyxoah Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Nyxoah (Nyxoah) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.